RADBIO

RADBIO is a small biotechnology company headquartered in Sunchales, United States. With a team of 5 employees, RADBIO generates an annual revenue of $2.5 million. The company is dedicated to tackling the debilitating effects of fibrosis, a major contributor to mortality in numerous diseases. RADBIO's core focus is on developing innovative therapeutic solutions targeting TGF-β, a cytokine recognized as the "Master Regulator of fibrosis." The company has identified a novel human protein, a unique soluble splice variant of the TGF-beta receptor 2, which serves as the foundation for its therapeutic platform. Through genetic engineering, RADBIO leverages this discovery to create new therapeutic assets. The company's platform allows for the design and development of tailored assets and delivery strategies, expanding the potential applications of its treatments while mitigating risks and enhancing their overall value. For further information, please visit RADBIO's website at radbiopharm.com.